Scientists in Germany say they've made a nasal vaccine that can shut down a Covid-19 infection before the virus even reaches the body. The vaccine uses a live but weakened form of the coronavirus, which is then given to the body so it can learn to recognize and fight off the virus.
In experiments with hamsters, two doses of the vaccine were able to block the virus from copying itself in the animals' upper airways, achieving "sterilizing immunity" and preventing illness. This approach aims to boost mucosal immunity, which is the immune defense in the tissues that line the upper airways, right where the virus would land and begin to infect our cells.
The idea behind this approach is to create a vaccine that can prevent the virus from getting a foothold in the body before it's too late. The German team has used a technique called codon pair deoptimization to make the virus harder for cells to translate, which makes it easier for the immune system to recognize and attack.
The results of these experiments are promising, but more tests need to be done before the vaccine can be widely available. Researchers have already conducted animal studies, and now they're moving on to human trials. The development of this vaccine is seen as a potential game-changer in the fight against Covid-19, particularly for vulnerable groups such as the elderly and immunocompromised individuals.
However, experts caution that there are still many hurdles to clear before the vaccine can be widely used. These include issues related to cost, accessibility, and the potential risks of using live but weakened viruses. The German team is now working with a Swiss company to start phase I clinical trials, which will help determine whether this approach is promising or not.
While there have been several nasal vaccines in development, many experts agree that more work needs to be done before we can say that Covid-19 is under control. The World Health Organization's vaccine tracker shows that at least four nasal vaccines for Covid-19 are now reaching late-stage testing in humans. However, the progress has been slow and halting, with many groups struggling to raise the costs of getting a new vaccine to market.
The development of a pan-coronavirus vaccine that induces mucosal immunity is seen as a key goal, particularly given the potential for new variants of the virus. The use of live attenuated viruses in vaccines has shown promise in other areas, such as measles and flu vaccination, but there are also concerns about the risks of using these types of vaccines, particularly for individuals with compromised immune systems.
Ultimately, the development of an effective Covid-19 vaccine will require a combination of scientific innovation, careful consideration of potential risks, and a commitment to making these vaccines accessible to those who need them most.
In experiments with hamsters, two doses of the vaccine were able to block the virus from copying itself in the animals' upper airways, achieving "sterilizing immunity" and preventing illness. This approach aims to boost mucosal immunity, which is the immune defense in the tissues that line the upper airways, right where the virus would land and begin to infect our cells.
The idea behind this approach is to create a vaccine that can prevent the virus from getting a foothold in the body before it's too late. The German team has used a technique called codon pair deoptimization to make the virus harder for cells to translate, which makes it easier for the immune system to recognize and attack.
The results of these experiments are promising, but more tests need to be done before the vaccine can be widely available. Researchers have already conducted animal studies, and now they're moving on to human trials. The development of this vaccine is seen as a potential game-changer in the fight against Covid-19, particularly for vulnerable groups such as the elderly and immunocompromised individuals.
However, experts caution that there are still many hurdles to clear before the vaccine can be widely used. These include issues related to cost, accessibility, and the potential risks of using live but weakened viruses. The German team is now working with a Swiss company to start phase I clinical trials, which will help determine whether this approach is promising or not.
While there have been several nasal vaccines in development, many experts agree that more work needs to be done before we can say that Covid-19 is under control. The World Health Organization's vaccine tracker shows that at least four nasal vaccines for Covid-19 are now reaching late-stage testing in humans. However, the progress has been slow and halting, with many groups struggling to raise the costs of getting a new vaccine to market.
The development of a pan-coronavirus vaccine that induces mucosal immunity is seen as a key goal, particularly given the potential for new variants of the virus. The use of live attenuated viruses in vaccines has shown promise in other areas, such as measles and flu vaccination, but there are also concerns about the risks of using these types of vaccines, particularly for individuals with compromised immune systems.
Ultimately, the development of an effective Covid-19 vaccine will require a combination of scientific innovation, careful consideration of potential risks, and a commitment to making these vaccines accessible to those who need them most.